Page last updated: 2024-10-20

pyridoxamine and Disease Models, Animal

pyridoxamine has been researched along with Disease Models, Animal in 11 studies

Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.

Research Excerpts

ExcerptRelevanceReference
" In the current manuscript, we studied the effect of pyridoxamine (PM) on protein glycation, oxidative stress, interleukin-1α (IL-1α), IL-6, C-reactive protein (CRP), gene expression of tumour necrosis factor-α (TNF-α) and transforming growth factor-β1 (TGF-β1) in relation to microalbuminuria and kidney functions in a model of alloxan-induced diabetic rats."7.79Pyridoxamine, an inhibitor of protein glycation, in relation to microalbuminuria and proinflammatory cytokines in experimental diabetic nephropathy. ( Elseweidy, MM; Elswefy, SE; Younis, NN; Zaghloul, MS, 2013)
" In the current manuscript, we studied the effect of pyridoxamine (PM) on protein glycation, oxidative stress, interleukin-1α (IL-1α), IL-6, C-reactive protein (CRP), gene expression of tumour necrosis factor-α (TNF-α) and transforming growth factor-β1 (TGF-β1) in relation to microalbuminuria and kidney functions in a model of alloxan-induced diabetic rats."3.79Pyridoxamine, an inhibitor of protein glycation, in relation to microalbuminuria and proinflammatory cytokines in experimental diabetic nephropathy. ( Elseweidy, MM; Elswefy, SE; Younis, NN; Zaghloul, MS, 2013)
" Metabolic profile, NO bioavailability and vascular oxidative stress, AGE and Nrf2 levels were also assessed."1.46The Sulforaphane and pyridoxamine supplementation normalize endothelial dysfunction associated with type 2 diabetes. ( Crisóstomo, J; Fernandes, R; Pereira, A; Seiça, RM; Sena, CM, 2017)
"A mouse model for diabetic nephropathy that encompasses the salient features of this disease in the kidney is not available."1.34Renal fibrosis and glomerulosclerosis in a new mouse model of diabetic nephropathy and its regression by bone morphogenic protein-7 and advanced glycation end product inhibitors. ( Grahovac, G; Kalluri, R; Sugimoto, H; Zeisberg, M, 2007)
"Pyridoxamine treatment resulted in significantly lower (by approximately 50%) levels of urinary glycolate and oxalate excretion compared to untreated hyperoxaluric animals."1.33Pyridoxamine lowers kidney crystals in experimental hyperoxaluria: a potential therapy for primary hyperoxaluria. ( Belmont, JM; Chetyrkin, SV; Hudson, BG; Kim, D; Scheinman, JI; Voziyan, PA, 2005)

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (27.27)29.6817
2010's7 (63.64)24.3611
2020's1 (9.09)2.80

Authors

AuthorsStudies
Kamphuis, JBJ1
Guiard, B1
Leveque, M1
Olier, M1
Jouanin, I1
Yvon, S1
Tondereau, V1
Rivière, P1
Guéraud, F1
Chevolleau, S1
Noguer-Meireles, MH1
Martin, JF1
Debrauwer, L1
Eutamène, H1
Theodorou, V1
Pereira, A1
Fernandes, R1
Crisóstomo, J1
Seiça, RM1
Sena, CM1
Illien-Junger, S1
Grosjean, F1
Laudier, DM1
Vlassara, H1
Striker, GE1
Iatridis, JC1
Elseweidy, MM1
Elswefy, SE1
Younis, NN1
Zaghloul, MS1
Dong, Z1
Iwata, D1
Kitaichi, N1
Takeuchi, M1
Sato, M1
Endo, N1
Iwabuchi, K1
Ando, R1
Fukuhara, J1
Kinoshita, S1
Lennikov, A1
Kitamura, M1
Mizuuchi, K1
Kanda, A1
Noda, K1
Namba, K1
Yamagishi, S1
Ohno, S1
Ishida, S1
Ren, X1
Sun, H1
Zhang, C1
Li, C1
Wang, J1
Shen, J1
Yu, D1
Kong, L1
Mori, Y1
Kakuta, T1
Miyakogawa, T1
Takekoshi, S1
Yuzawa, H1
Kobayashi, H1
Kawakami, A1
Miyata, T1
Fukagawa, M1
Jones, DC1
Alphey, MS1
Wyllie, S1
Fairlamb, AH1
Chetyrkin, SV1
Kim, D1
Belmont, JM1
Scheinman, JI1
Hudson, BG1
Voziyan, PA1
Coughlan, MT1
Cooper, ME1
Forbes, JM1
Sugimoto, H1
Grahovac, G1
Zeisberg, M1
Kalluri, R1

Reviews

1 review available for pyridoxamine and Disease Models, Animal

ArticleYear
Can advanced glycation end product inhibitors modulate more than one pathway to enhance renoprotection in diabetes?
    Annals of the New York Academy of Sciences, 2005, Volume: 1043

    Topics: Animals; Diabetic Nephropathies; Disease Models, Animal; Glycation End Products, Advanced; Guanidine

2005

Other Studies

10 other studies available for pyridoxamine and Disease Models, Animal

ArticleYear
Lactose and Fructo-oligosaccharides Increase Visceral Sensitivity in Mice via Glycation Processes, Increasing Mast Cell Density in Colonic Mucosa.
    Gastroenterology, 2020, Volume: 158, Issue:3

    Topics: Abdominal Oblique Muscles; Animals; Colon; Diet; Disease Models, Animal; Electromyography; Feces; Fe

2020
The Sulforaphane and pyridoxamine supplementation normalize endothelial dysfunction associated with type 2 diabetes.
    Scientific reports, 2017, 10-30, Volume: 7, Issue:1

    Topics: Animals; Aorta; Diabetes Mellitus, Type 2; Dietary Supplements; Disease Models, Animal; Endothelium;

2017
Combined anti-inflammatory and anti-AGE drug treatments have a protective effect on intervertebral discs in mice with diabetes.
    PloS one, 2013, Volume: 8, Issue:5

    Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Diabetes Mellitus, Experimental; Disease Mo

2013
Pyridoxamine, an inhibitor of protein glycation, in relation to microalbuminuria and proinflammatory cytokines in experimental diabetic nephropathy.
    Experimental biology and medicine (Maywood, N.J.), 2013, Aug-01, Volume: 238, Issue:8

    Topics: Albuminuria; Alloxan; Animals; C-Reactive Protein; Cytokines; Diabetes Mellitus, Experimental; Diabe

2013
Amelioration of experimental autoimmune uveoretinitis by inhibition of glyceraldehyde-derived advanced glycation end-product formation.
    Journal of leukocyte biology, 2014, Volume: 96, Issue:6

    Topics: Administration, Oral; Adult; Amino Acid Sequence; Animals; Autoimmune Diseases; Behcet Syndrome; Dis

2014
Protective function of pyridoxamine on retinal photoreceptor cells via activation of the p‑Erk1/2/Nrf2/Trx/ASK1 signalling pathway in diabetic mice.
    Molecular medicine reports, 2016, Volume: 14, Issue:1

    Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Disease M

2016
Effect of Scavenging Circulating Reactive Carbonyls by Oral Pyridoxamine in Uremic Rats on Peritoneal Dialysis.
    Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 2016, Volume: 20, Issue:6

    Topics: Administration, Oral; Animals; Dialysis Solutions; Disease Models, Animal; Kidney Failure, Chronic;

2016
Chemical, genetic and structural assessment of pyridoxal kinase as a drug target in the African trypanosome.
    Molecular microbiology, 2012, Volume: 86, Issue:1

    Topics: Amino Acid Sequence; Animals; Antiprotozoal Agents; Disease Models, Animal; Enzyme Inhibitors; Gene

2012
Pyridoxamine lowers kidney crystals in experimental hyperoxaluria: a potential therapy for primary hyperoxaluria.
    Kidney international, 2005, Volume: 67, Issue:1

    Topics: Animals; Calcium Oxalate; Crystallization; Disease Models, Animal; Glyoxylates; Humans; Hyperoxaluri

2005
Renal fibrosis and glomerulosclerosis in a new mouse model of diabetic nephropathy and its regression by bone morphogenic protein-7 and advanced glycation end product inhibitors.
    Diabetes, 2007, Volume: 56, Issue:7

    Topics: Animals; Bone Morphogenetic Protein 7; Bone Morphogenetic Proteins; Diabetic Nephropathies; Disease

2007
chemdatabank.com